InsidersTradesSigma
Selecta Biosciences INC Stock: price and management transactions · United States · SEC (Form 4)
Follow the Selecta Biosciences INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Selecta Biosciences INC has logged 104 insider filings. The latest transaction was filed on 26 September 2023 (Cession). Among the most active insiders: Brunn Carsten. All data is free.
104
Insider Decl.
0
Thresholds
€40m
23 ops.
Buy Volume
€556,580
32 ops.
Sell Volume
41Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 26 September 2023
Declarations104 total
2,932 shares@ US$1.060.9% of flowCommon StockSEC:0001453687-23-000068:0
705 shares@ US$1.060.3% of flowCommon StockSEC:0001453687-23-000067:0
43,000 shares0Common StockSEC:0001453687-23-000054:0
8,164 shares@ US$1.13373.2% of flowCommon StockSEC:0001453687-23-000032:0
6,381 shares@ US$1.13378.8% of flowCommon StockSEC:0001453687-23-000034:0
6,381 shares@ US$1.13374.9% of flowCommon StockSEC:0001453687-23-000033:0
27,549 shares@ US$1.13379.1% of flowCommon StockSEC:0001453687-23-000035:0
200,000 shares0Common StockSEC:0001453687-23-000015:0
100,000 shares0Common StockSEC:0001453687-23-000018:0
282,800 shares0Common StockSEC:0001453687-23-000022:0
100,000 shares0Common StockSEC:0001453687-23-000019:0
4,522 shares@ US$1.331.8% of flowCommon StockSEC:0001453687-22-000147:0
10,938 shares0Common StockSEC:0001453687-22-000145:0
2,692 shares@ US$1.66051.4% of flowCommon StockSEC:0001453687-22-000131:0
10,937 shares0Common StockSEC:0001453687-22-000129:0
130,000 shares@ US$1.152361.6% of flowCommon StockSEC:0001453687-22-000104:0
Ideal exit: 10 Mar 2023 (T+270)
10,938 shares0Common StockSEC:0001453687-22-000099:0
50,000 shares@ US$0.774427.2% of flowCommon StockSEC:0001453687-22-000090:0
Ideal exit: 3 Feb 2023 (T+270)
6,681,600 sharesCommon StockSEC:0001453687-22-000057:0
Ideal exit: 6 Jan 2023 (T+270)
10,937 shares0Common StockSEC:0001453687-22-000044:0
10,000 shares@ US$2.1037.3% of flowCommon StockSEC:0001453687-22-000036
10,000 shares@ US$2.1013.6% of flowCommon StockSEC:0001453687-22-000036:0
3,416 shares@ US$3.085914.0% of flowCommon StockSEC:0001453687-22-000033
3,226 shares@ US$3.08596.6% of flowCommon StockSEC:0001453687-22-000034
13,597 shares@ US$3.085926.4% of flowCommon StockSEC:0001453687-22-000031
25 of 104 declarations
About Selecta Biosciences INC
Selecta Biosciences Inc. is a United States biotechnology company historically listed on the NASDAQ under the ticker SELB. The company was incorporated in 2007 and was based in Watertown, Massachusetts, in the Greater Boston life-sciences cluster. Its scientific positioning centered on immune modulation through its proprietary ImmTOR® platform, designed to selectively reduce unwanted immune responses and improve tolerance to biologic therapies. In practical terms, Selecta aimed to address a core challenge in advanced biologics: immunogenicity, which can limit durability, safety, and efficacy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1453687/000145368719000032/selectabiosciences10-k.htm?utm_source=openai)) For much of its life as a standalone public biotech, Selecta operated as a clinical-stage company rather than a commercial-stage pharmaceutical group. That profile meant minimal or no product revenue and a business model highly dependent on clinical execution, capital access, and strategic partnerships. The company’s best-known program was SEL-212, a combination product developed for chronic refractory gout, where the goal was to durably control uric acid and reduce the burden of urate crystal deposits. Over time, Selecta also discussed broader opportunities for the ImmTOR platform in therapeutic areas where dampening immune responses could enhance the profile of biologic medicines. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1453687/000145368723000040/selb-20221231.htm?utm_source=openai)) From an equity research perspective, Selecta represented a classic binary-value biotech: the investment case depended heavily on clinical data, regulatory milestones, financing conditions, and partnership potential. Companies in this category can be highly volatile, but they can also re-rate sharply when trial outcomes are positive or when an industry partner validates the platform. That makes Selecta especially relevant for investors who follow SEC Form 4 insider transactions, because insider activity in development-stage biotech often needs to be interpreted alongside pipeline risk and capital structure considerations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1453687/000145368723000040/selb-20221231.htm?utm_source=openai)) Geographically, the company’s operational footprint was predominantly U.S.-based, with its Boston-area headquarters anchoring its research and corporate functions. Its competitive position was shaped less by geographic scale and more by the novelty of its immune-tolerization technology and the breadth of its potential applications across biologics. A crucial market note for investors: in November 2023, Selecta Biosciences merged with Cartesian Therapeutics, and the listed entity was renamed, so SELB is an historical NASDAQ identifier rather than the current trading name of a standalone company. That distinction matters when reviewing recent filings, ownership changes, or insider transactions tied to the legacy Selecta vehicle. ([nasdaq.com](https://www.nasdaq.com/articles/selecta-biosciences-merges-with-cartesian-therapeutics-in-all-stock-deal?time=1699882306&utm_source=openai))
